Sato Masahiko, Narukawa Mamoru
Int J Clin Pharmacol Ther. 2017 Oct;55(10):798-806. doi: 10.5414/CP202966.
Acid-reducing agents (ARAs) may affect drug exposure for orally-administered drugs exhibiting pH-dependent solubility. The aim of this research was to investigate factors predicting the effect of ARAs on drug exposure. Dose (mg)/250 mL/solubility at neutral pH and ratio of solubility at acidic pH to that at neutral pH were investigated as potential factors.
Drug-drug interaction (DDI) study results with ARAs were selected based on PubMed search from 2007 to 2016 and novel drug approvals at the US Food and Drug Administration (FDA) from 2014 to 2016. For the selected drugs, solubility data at acidic and neutral pH were obtained from publications, FDA and European Medicines Agency (EMA) review report, and Japanese interview form.
32 DDI study results with ARAs from 27 drugs having solubility data were obtained. The effect of ARAs on the C or AUC ratio% (with/without ARAs) decreased with the increasing values of both factors, but the ratio of solubility showed higher values of squared correlation coefficient R2 (0.75 - 0.78) than the dose (mg)/250 mL/solubility at neutral pH (0.48 - 0.59).
CONCLUSION: Ratio of solubility at acidic pH to that at neutral pH was a good predictor to estimate the effect of ARAs on drug exposure. Prediction of the effect of ARAs on drug exposure using solubility data would help to consider the necessity and timing for conducting a dedicated DDI study with ARAs and contribute to efficient drug development. .
对于口服的呈现pH依赖性溶解度的药物,抑酸剂(ARAs)可能会影响药物暴露量。本研究的目的是调查预测ARAs对药物暴露量影响的因素。研究了剂量(mg)/250 mL/中性pH下的溶解度以及酸性pH下的溶解度与中性pH下的溶解度之比作为潜在因素。
基于2007年至2016年的PubMed搜索以及2014年至2016年美国食品药品监督管理局(FDA)的新药批准情况,筛选了ARAs的药物相互作用(DDI)研究结果。对于所选药物,从出版物、FDA和欧洲药品管理局(EMA)审评报告以及日本访谈表格中获取酸性和中性pH下的溶解度数据。
获得了来自27种有溶解度数据的药物的32项ARAs的DDI研究结果。ARAs对C或AUC比值%(有/无ARAs)的影响随着这两个因素值的增加而降低,但溶解度之比的平方相关系数R2值(0.75 - 0.78)高于剂量(mg)/250 mL/中性pH下的溶解度(0.48 - 0.59)。
酸性pH下的溶解度与中性pH下的溶解度之比是估计ARAs对药物暴露量影响的良好预测指标。利用溶解度数据预测ARAs对药物暴露量的影响将有助于考虑开展ARAs专项DDI研究的必要性和时机,并有助于高效的药物研发。